Aclarion

Aclarion Gross Margin

The Gross Margin of Aclarion (ACON) as of Oct 21, 2026 is -291.27 %. In the previous year, Gross Margin was -183.81 % — a change of 58.47% (lower).

Gross Margin

-291.27 %

YoY

58.47%

Last updated:

Gross Margin of Aclarion is 2025 -291.27 % . Gross Margin of Aclarion was 2024 -183.81 % . It decreases by 58.47% lower compared to the previous year.

Aclarion's gross margin stands at -291.3%, down from -14.7% several years earlier.

The Aclarion Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
-134.90 USD
Jan 1, 2020
-36.16 USD
Jan 1, 2021
-14.73 USD
Jan 1, 2022
-8.03 USD
Jan 1, 2023
-0.43 USD
Jan 1, 2024
-183.81 USD
Jan 1, 2025
-291.27 USD
The Aclarion Gross Margin history
YEARGross MarginYoY
-291.27 %+58.47%
-183.81 %+42,676.64%
-0.43 %-94.65%
-8.03 %-45.49%
-14.73 %-59.26%
-36.16 %-73.19%
-134.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aclarion Stock analysis

What does Aclarion do? Aclarion, Inc. generates revenue through its proprietary biomarker technology and signal processing software, which transforms raw Magnetic Resonance Spectroscopy (MRS) data into metabolic biomarkers for clinical use. The company's products are utilized by physicians to differentiate between painful and nonpainful lumbar spine discs, leveraging augmented intelligence in post-processing algorithms to quantify biomarker data and produce individualized ratio metrics against normative datasets. The firm targets healthcare providers focused on chronic low back pain treatment, offering solutions that optimize clinical decision-making through metabolic analysis. Aclarion's technology is centered on Magnetic Resonance Spectroscopy (MRS) and its proprietary biomarker, designed to assist physicians in determining disc-related pain in the lumbar spine. The company's signal processing software and expert system convert raw spectral MRS data into clear, actionable biomarkers, enabling tailored treatment approaches for chronic low back pain patients. By focusing exclusively on this clinical application, Aclarion serves a specialized segment of healthcare providers seeking advanced diagnostic tools for spinal conditions. Aclarion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aclarion stock

Gross Margin of Aclarion is -291.27 % in 2025.

Gross Margin of Aclarion changed from -183.81 % to -291.27 %, representing a 58.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Aclarion since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Aclarion with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Aclarion

All Key Metrics — Aclarion